Abstract. estrogen receptor α (er α ) mediates most of the biological effects of estrogen in mammary epithelial cells and stimulates growth signals involving phosphoinositide-3-oH kinase (Pi3K)/akt in breast cancer cells. Phosphatase and tensin homologue (PTen) is a critical counter-regulator of Pi3K signaling and is thus one of the major tumor suppressors in breast cancer. inhibition of Pi3K with an inhibitor, wortmannin, increased the level of PTen protein in er α -positive McF-7 cells, while levels in er α -negative Mda-MB 231 cells were not altered. in addition, the level of PTen protein in MCF-7 cells was significantly lower than that in MDA-MB 231 cells, which correlated with high levels of phospho-akt and phosphatidylinositol-3,4,5,-trisphosphate (PiP 3 ). However, PTen mrna expression as measured by real-time Pcr showed no differences in either cell line. notably, the levels of casein kinase 2 (cK2) and phospho-PTen (Ser380/ Thr382/383) in McF-7 cells were lower than those in Mda-MB 231 cells, indicating that the down-regulation of PTen protein in McF-7 cells is caused by low levels of cK2 expression, leading to accelerated PTen degradation. collectively, these results suggest that er α induces the down-regulation of PTen through Pi3K activation in breast cancer cells.
Introduction
Phosphatase and tensin homologue (PTen) on chromosome 10q23 is phosphatidylinositol-3' phosphatase (lipid phosphatase) that dephosphorylates the d3 position of phosphatidylinositol-3,4,5-trisphosphate (PiP 3 ), a second messenger that is produced by phosphatidylinosititol-3-oH kinase (Pi3K) and activates protein kinase B (PKB)/akt (1) (2) (3) .
PTen is known to be one of the major tumor suppressor genes in human cancer and plays a pivotal role in the carcinogenesis of breast cancer cells. PTen inhibits breast cancer growth through the down-regulation of Pi3K signaling, resulting in the blockage of cell cycle progression and the induction of cell death (4) . along the same lines, PTen has been shown to arrest cells in the G 1 phase of the cell cycle in breast cancer cell lines (5) . These observations suggest that PTen is involved in the modulation of growth and survival in breast cancer cells. Mutations and/or deletions of PTen are found in a variety of cancer cells, including endometrial and breast neoplasm cells (4, (6) (7) (8) (9) (10) (11) (12) . in addition, reduced expression of PTen protein has been observed in approximately one third of all breast cancer cases (13) . Moreover, the reduced expression of PTen protein correlates with lymph node metastasis and a worse prognosis in patients with breast cancer (13) (14) (15) . However, the down-regulating mechanism of PTen in breast cancer cells remains to be clarified.
estrogen plays critical roles in the proliferation of breast cancer cells via two estrogen receptors, estrogen receptor (er) α and er β , which are ligand-dependent transcription factors that belong to the superfamily of nuclear receptors. in breast cancer, the expression of the ers is correlated with well-differentiated of tumors and indicates a favorable prognosis, with responsiveness to endocrine therapy with anti-estrogen drugs (16, 17) . The transcription activities of the ers are regulated by interacting proteins, such as coactivators and kinases as well as ligand-binding proteins (18) . er α binds to the p85 regulatory subunit of Pi3K in a ligand-dependent manner, thereby activating akt and subsequently its downstream effectors (19) . We have also demonstrated that er α stimulates growth signals involving Pi3K/akt in breast cancer cells expressing both er α and er β (15). These findings indicate that a Pi3K-involved signaling system may be related to the biology of er α in breast cancer cells.
one of the traits of cancer cells is an imbalance in signal regulation, and er α mediates most of the biological effects of estrogen in mammary epithelial cells. To elucidate the role of er α and er β in the growth of cancer cells, we investigated the regulation of the Pi3K signaling system involving PTen, a counter-regulator of Pi3K signaling, in breast cancer cells. Two types of human breast epithelial cell lines were utilized: McF-7 cells, expressing both er α and er β , and Mda-MB-231 cells, expressing er β only. Western blot analysis. after washing with PBS and harvesting, cell pellets were lysed with 40 µl of ice-cold M-Per ® Mammalian Protein extraction reagent (Pierce Biotechnology, rockford, il, uSa). Protein concentrations in the lysate were determined using the Bradford method (20) . Samples (30 µg) were separated by SdS-PaGe with 10% acrylamide running and 3% acrylamide stacking gels, and then transferred to hybond™-PVdF membranes using a Western blot apparatus. The PVdF membranes were blotted with 1 µg/ml of primary antibodies for PTen, p-PTen, p-akt, cK2 and β-actin. Horseradish peroxidase-conjugated igG was used as a secondary antibody. Protein expression levels were then determined by analyzing the signals captured on the PVdF membranes using an image analyzer (las-1000, Fuji-Film, Japan). 3 levels. The intracellular PiP 3 level was determined by immunocytochemistry using a monoclonal antibody against PiP 3 as described by Niswender (21) . Briefly, cells mounted on glass slides were equilibrated in PBS at room temperature and then fixed in 4% paraformaldehyde at room temperature for 5-10 min. after blocking in a blocking buffer containing 5% normal goat serum and 2% bovine serum albumin, samples were incubated with a PiP 3 monoclonal antibody (echelon at a 1:100 dilution) overnight at 4˚C. The negative control for the antibody was an equivalent concentration of non-immune mouse igM. The immunoreactivity of PiP 3 was detected with goat anti-mouse igM-TriTc at a 1:200 dilution by incubation for 1 h at 4˚C. Samples were mounted in aqueous mounting medium with anti-fading agents. images were acquired with a confocal laser scanning biological microscope (FV 1000; olympus, Japan).
Materials and methods

Materials
Measurement of PIP
Quantitative real-time PCR assay. Total rna was extracted from the cells using Trizol reagent (invitrogen, carlsbad, ca, uSa). The concentration and purity of rna were determined at 260/280 nm. dna strands were synthesized from 1 µg total rna using oligo-dT primers and aMV reverse transcriptase (Takara, Japan). The expression of PTen mrna was determined by real-time reverse transcription-Pcr using the aBi-PriSM 7900 sequence detection system (applied Biosystems, Foster city, ca, uSa) and the SYBr Premix ex Taq (Takara). The primers for real-time reverse transcription-Pcr measurement were PTen primer (nM 002424.2) and 18Srrna primer (X03205.1) (Superarray Bioscience co., Frederick, Md, uSa). To control variations in mrna concentrations, the results were normalized to a housekeeping gene, 18srna. relative quantitation was performed using a comparative ∆∆ct method according to the manufacturer's instructions.
Statistical analysis. Statistical data analysis was performed using anoVa and duncan's test. differences with a p-value <0.05 were considered statistically significant.
Results
PI3K modulates PTEN protein levels in human breast cancer cells.
To examine the effect of Pi3K on PTen expression, er α -positive McF-7 and er α -negative Mda-MB 231 cells were incubated with 1 and 5 µM of wortmannin, a Pi3K inhibitor, for 24 h, and the levels of PTen protein were determined by Western blotting. as shown in Fig. 1 , treatment of McF-7 cells with the inhibitors resulted in a dose-dependent increase in the levels of PTen protein; PTen levels were increased by approximately 130% compared to the control cells. Supporting these results, the levels of p-akt were decreased (Fig. 1a) . However, PTen levels in Mda-MB 231 cells were not affected by treatment with wortmannin (Fig. 1B) .
ER α down-regulates PTEN protein levels in human breast cancer cells. We and others have shown that er α activates Pi3K in breast cancer cells (15,19). The above results indicate that Pi3K modulates PTen expression. Therefore, PTen expression profiles and p-Akt levels in ER α -positive McF-7 cells and er α -negative Mda-MB 231 cells were determined by Western blotting. PTen protein levels in er α -positive MCF-7 cells were significantly lower compared to those in er α -negative Mda-MB 231 cells, whereas p-akt levels in McF-7 cells were higher than those in Mda-MB 231 cells (Fig. 2) . To verify these observations, PiP 3 levels were also measured using immunocytochemistry. as shown in Fig. 3 , PiP 3 levels in er α -positive McF-7 cells were approximately 20-fold higher than those in er α -negative Mda-MB 231 cells.
ER α destabilizes PTEN protein by dephosphorylation in human breast cancer cells. Phosphorylation of PTen by cK2
has been shown to modulate the stability of PTen protein (22) . To elucidate the mechanism of PTen down-regulation in er α -positive McF-7 cells, the levels of PTen mrna, p-PTen and cK2 were determined. There were no differences in the expression of PTen mrna between er α -positive McF-7 cells and er α -negative Mda-MB 231 cells (Fig.  4a) . However, the levels of p-PTen (Ser380/Thr382/383) in MCF-7 cells were significantly lower than those in MDA-MB 231 cells (Fig. 4B ). in addition, the levels of cK2 in McF-7 cells were significantly lower than those in MDA-MB 231 cells (Fig. 4c) . These results suggest that the down-regulation of PTen protein in er α -positive breast cancer cells is caused by low levels of cK2 expression, leading to a decrease in the phosphorylation of PTen. in this study, we found that a decrease in PTen levels in er α -positive McF-7 cells was due to the degradation of the protein, but not its synthesis. Thus, the levels of PTen mrna were similar to each other in both er α -positive McF-7 cells and er α -negative Mda-MB-231 cells. However, the levels of p-PTen (Ser380/Thr382/383) in er α -positive McF-7 cells were significantly lower than those in ER α -negative Mda-MB 231 cells. Structurally, PTen is composed of an N-terminal dual specificity phosphatase-like enzyme domain and a c-terminal regulatory domain, which binds to the phospholipid membrane (26) . The c-terminal PTen domain is rich in putative phosphorylation sites, and phosphorylation of the PTen c-terminus has been reported to affect PTen stability and function (27) .
Protein kinase cK2 is a messenger-independent serine/ threonine-kinase that phosphorylates a wide variety of substrates involved in essential cell processes, including cell cycle progression and growth (28, 29) . cK2 is the major kinase involved in the phosphorylation of PTen, and cK2 phosphorylation sites in PTen are located within a c-terminal cluster of Ser/Thr residues (30) . in addition, inhibition of PTen phosphorylation with a cK2 inhibitor reduces PTen protein content, suggesting that proper phosphorylation of PTen by cK2 is important for the stability of PTen protein in proteasome-mediated degradation (22) . in the present study, we found that the levels of cK2 in McF-7 cells were significantly lower than those in MDA-MB 231 cells. Taken together, these observations suggest that the down-regulation of PTen protein in er α -positive breast cancer cells is caused by low levels of cK2 expression, leading to accelerated PTen degradation.
in conclusion, our results indicate that PTen is down-regulated in er α -positive, but not in er α -negative, breast cancer cells, and that the down-regulation of PTen is caused by the reduced phosphorylation of PTen. The results also suggest that PTen expression is regulated through Pi3K signaling involving er α in breast cancer cells. Since deletion or reduced expression of PTen is known to be associated with poor outcome in breast cancer, our findings may aid in the design 
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of novel therapeutic strategies as well as in the diagnosis of er α -positive breast cancer.
